National Research Corporation Announces Second Quarter 2021 Results
National Research Corporation reported strong Q2 2021 results, achieving a 17% revenue increase to $36.4 million and a 32% rise in operating income to $12.2 million. The total recurring contract value grew 5% to $149.8 million, driven by a 29% boost in Voice of the Customer offerings. The cash balance increased to $48.9 million. However, the effective tax rate rose to 25% from 10% in the previous year, impacting net income which reached $8.9 million, up from $7.7 million. The company focuses on organic growth and enhancing client relationships.
- 17% revenue increase to $36.4 million in Q2 2021.
- 32% increase in operating income to $12.2 million.
- Recurring contract value grew 5% to $149.8 million.
- Voice of the Customer revenue rose 29% in Q2 2021.
- Cash balance increased to $48.9 million.
- Effective tax rate jumped to 25% from 10% year-over-year.
- Net income decreased year-to-date from $19.5 million in 2020 to $18.2 million in 2021.
LINCOLN, Neb., Aug. 03, 2021 (GLOBE NEWSWIRE) -- National Research Corporation (NASDAQ:NRC) today announced results for the second quarter of 2021.
Financial Results (Q2 2021 compared to Q2 2020):
- Total Recurring Contract Value growth of
5% to$149.8 million - Revenue increased
17% to$36.4 million - Operating Income increased
32% to$12.2 million
We saw significant improvement in revenue growth in the second quarter which is in line with our continued focus on increasing our revenue growth rate and enabling human understanding for the clients we serve. Our primary emphasis is on organic growth levers of increasing revenue from our core offerings within our existing client base, as well as adding new clients to increase market share. As a result, revenue from our Voice of the Customer offerings increased by
We believe our solutions are highly differentiated in our clients’ eyes against competitive offerings from firms outside of the healthcare industry and legacy vendors within as we continue to add new clients. We believe that every added client deepens our moat and brings additive value to all current partners through the network effect and the efficiencies inherent in our subscription model have led to long-term margin improvements, a hallmark of our financial performance.
Our cash balance increased to
Second quarter 2021 revenue was
Total operating expenses of
Direct expenses increased to
Selling, general and administrative expenses increased to
Depreciation, amortization and impairment expense increased to
Other income and expense was
The Company had an income tax provision of
Net income for second quarter 2021 was
On a year-to-date basis, 2021 revenue increased by
For more than 40 years, National Research Corporation has been a leading provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers and other healthcare organizations in the United States and Canada. Our purpose is to enable human understanding by helping our clients to understand the voice of the customer with greater clarity, immediacy and depth.
This press release contains certain statements that may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such statements are subject to the safe harbor created by those sections and the Private Securities Litigation Reform Act of 1995, as amended. Such statements may be identified by their use of terms or phrases such as “believes,” “expect,” derivations thereof, and similar terms and phrases. Forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, which could cause future events and actual results to differ materially from those set forth in, contemplated by, or underlying the forward-looking statements, including those risks and uncertainties as set forth in the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2020 and various disclosures in our press releases, stockholder reports, and other filings with the Securities and Exchange Commission. In this press release, the statements relating to future M&A activity, future payment of dividends, and the future impact of adding additional clients are forward-looking statements. We disclaim any obligation to update or revise any forward-looking statements to reflect actual results or changes in the factors affecting the forward-looking information.
NATIONAL RESEARCH CORPORATION AND SUBSIDIARY
Unaudited Condensed Consolidated Statements of Income
(In thousands, except per share data)
Three months ended June 30, | Six months ended June 30, | ||||||||||||||||||||||
2021 | 2020 | 2021 | 2020 | ||||||||||||||||||||
Revenue | $ | 36,425 | $ | 31,166 | $ | 71,889 | $ | 65,026 | |||||||||||||||
Operating expenses: | |||||||||||||||||||||||
Direct expenses | 12,536 | 11,634 | 24,476 | 24,180 | |||||||||||||||||||
Selling, general and administrative | 10,016 | 8,852 | 19,536 | 17,600 | |||||||||||||||||||
Depreciation and amortization | 1,634 | 1,405 | 3,618 | 2,777 | |||||||||||||||||||
Total operating expenses | 24,186 | 21,891 | 47,630 | 44,557 | |||||||||||||||||||
Operating income | 12,239 | 9,275 | 24,259 | 20,469 | |||||||||||||||||||
Other income (expense): | |||||||||||||||||||||||
Interest income | 3 | 2 | 6 | 13 | |||||||||||||||||||
Interest expense | (423 | ) | (450 | ) | (855 | ) | (914 | ) | |||||||||||||||
Other, net | 75 | (270 | ) | 96 | 360 | ||||||||||||||||||
Total other expense | (345 | ) | (718 | ) | (753 | ) | (541 | ) | |||||||||||||||
Income before income taxes | 11,894 | 8,557 | 23,506 | 19,928 | |||||||||||||||||||
Provision for income taxes | 2,950 | 842 | 5,330 | 458 | |||||||||||||||||||
Net income | $ | 8,944 | $ | 7,715 | $ | 18,176 | $ | 19,470 | |||||||||||||||
Earnings Per Share of Common Stock: | |||||||||||||||||||||||
Basic Earnings Per Share | $ | 0.35 | $ | 0.31 | $ | 0.71 | $ | 0.78 | |||||||||||||||
Diluted Earnings Per Share | $ | 0.35 | $ | 0.30 | $ | 0.71 | $ | 0.76 | |||||||||||||||
Weighted average shares and share equivalents outstanding | |||||||||||||||||||||||
Basic | 25,426 | 25,148 | 25,420 | 25,060 | |||||||||||||||||||
Diluted | 25,645 | 25,680 | 25,656 | 25,702 | |||||||||||||||||||
NATIONAL RESEARCH CORPORATION AND SUBSIDIARY
Unaudited Condensed Consolidated Balance Sheets
(Dollars in thousands, except share amounts and par value)
June 30, | December 31, | |||||||
2021 | 2020 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 48,899 | $ | 34,690 | ||||
Accounts receivable, net | 14,157 | 13,923 | ||||||
Income taxes receivable | 153 | 1,235 | ||||||
Other current assets | 4,380 | 4,264 | ||||||
Total current assets | 67,589 | 54,112 | ||||||
Property and equipment, net | 11,525 | 11,726 | ||||||
Goodwill | 61,640 | 57,255 | ||||||
Other, net | 11,095 | 10,330 | ||||||
Total assets | $ | 151,849 | $ | 133,423 | ||||
Liabilities and Shareholders’ Equity | ||||||||
Current liabilities: | ||||||||
Current portion of notes payable, net unamortized debt issuance costs | $ | 4,168 | $ | 4,061 | ||||
Accounts payable and accrued expenses | 4,959 | 4,279 | ||||||
Accrued compensation | 7,075 | 6,460 | ||||||
Income taxes payable | 512 | -- | ||||||
Deferred revenue | 16,848 | 15,585 | ||||||
Other current liabilities | 3,364 | 1,296 | ||||||
Dividends payable | 3,053 | -- | ||||||
Total current liabilities | 39,979 | 31,681 | ||||||
Notes payable, net of current portion and unamortized debt issuance costs | 24,434 | 26,547 | ||||||
Other non-current liabilities | 11,071 | 10,880 | ||||||
Total liabilities | 75,484 | 69,108 | ||||||
Shareholders’ equity: | ||||||||
Preferred stock, | -- | -- | ||||||
Common stock, | 31 | 31 | ||||||
Additional paid-in capital | 172,844 | 171,785 | ||||||
Retained earnings (accumulated deficit) | (49,304 | ) | (61,375) | |||||
Accumulated other comprehensive loss, foreign currency translation adjustment | (2,269 | ) | (2,399) | |||||
Treasury stock | (44,937 | ) | (43,727) | |||||
Total shareholders’ equity | 76,365 | 64,315 | ||||||
Total liabilities and shareholders’ equity | $ | 151,849 | $ | 133,423 |
Contact:
Kevin R. Karas
Chief Financial Officer
402-475-2525
FAQ
What were National Research Corporation's Q2 2021 financial results?
How much did NRC's recurring contract value grow in Q2 2021?
What was the effective tax rate for NRC in Q2 2021?
What impacted NRC's net income year-to-date in 2021?